Comparison of Mechanism and Functional Effects of Magnesium and Statin Pharmaceuticals

REFERENCES

• Boden WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Fram ingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial.Am J Cardiol86 :19L– 22L,2000 .
   PubMed Web of Science ®Google Scholar
• McKenney JM: New guidelines for managing hypercholesterolemia.National Cholesterol Education Program. Am PharmNS33 :24– 32,1993 .
   Google Scholar
• Paulweber B: [Statins in primary prevention of coronary heart disease].Wien Med Wochenschr149 :129– 138,1999 .
   PubMedGoogle Scholar
• Endo A, Kuroda M, Terahara A, et al.:US Patent 3,983,140: Physiologically active substances. United States: Sankyo Company Limited (Tokyo, JA),1976 .
   Google Scholar
• Monaghan RL, Alberts AW, Hoffman CH, Albers-Schonberg G:US Patent 4,231,938: Hypocholesteremic fermentation products and process of preparation: Merck & Co., Inc. (Rahway, NJ),1980 .
   Google Scholar
• Terahara A, Tanaka M:US Patent 4,346,227: ML-236B Derivatives and their preparation: Sankyo Company, Limited (Tokyo, JP),1982 .
   Google Scholar
• Hoffman WF, Smith RL, Willard AK:US Patent 4,444,784: Antihypercholesterolemic compounds. United States: Merck & Co., Inc. (Rahway, NJ).1984 .
   Google Scholar
• Hoffman WF, Smith RL, Willard AK:US Patent 4,450,171: Antihypercholesterolemic compounds: Merck & Co., Inc. (Rahway, NJ).1984 .
   Google Scholar
• King MW:Cholesterol and Bile Metabolism: Biosynthesis of Cholesterol, Regulation of Cholesterol Synthesis , Indiana State Univ, School of Medicine,2002 .
   Google Scholar
• Chen H, Ikeda U, Shimpo M, Shimada K: Direct effects of statins on cells primarily involved in atherosclerosis.Hypertens Res23 :187– 192,2000 .
   PubMed Web of Science ®Google Scholar
• Davignon J, Mabile L: [Mechanisms of action of statins and their pleiotropic effects].Ann Endocrinol (Paris)62 :101– 112,2001 .
   PubMed Web of Science ®Google Scholar
• Faggiotto A, Paoletti R: Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?Curr Atheroscler Rep2 :20– 25,2000 .
   PubMedGoogle Scholar
• Hughes AD: The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.J Hum Hypertens10 :387– 301,1996 .
   PubMedGoogle Scholar
• Hulcher FH: Inhibition of hepatic cholesterol biosynthesis by 3,5-dihydroxy-3,4,4-trimethylvaleric acid and its site of action.Arch Biochem Biophys146 :422– 427,1971 .
   PubMedGoogle Scholar
• Chow JD, Higgins MP, Rudney H: The inhibitory effect of ATP on HMG CoA reductase.Biochem Biophys Res Comnmun63 :1077– 1084,1975 .
   Google Scholar
• Ferrer A, Hegardt FG: Phosphorylation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mirosomal 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase.Arch Biochem Biophys230 :227– 237,1984 .
   PubMedGoogle Scholar
• Ferrer A, Caelles C, Massot N, Hegardt FG: Allosteric activation of rat liver microsomal [hydroxymethylglutaryl-CoA reductase (NADPH)]kinase by nucleoside phosphates.Biol Chem Hoppe Seyler368 :249– 257,1987 .
   PubMedGoogle Scholar
• Gil G, Calvet VE, Ferrer A, Hegardt FG: Inactivation and reactivation of rat liver 3-hydroxy-3-methylglutaryl-CoA-reductase phosphatases: effect of phosphate, pyrophosphate and divalent cations.Hoppe Seylers Z Physiol Chem363 :1217– 1224,1982 .
   PubMedGoogle Scholar
• Gil G, Calvet VE, Asins G, Hegardt FG: Inactivation of rat liver HMG-CoA reductase phosphatases by nucleotides.Rev Esp Fisiol39 :259– 266,1983 .
   PubMedGoogle Scholar
• Beg ZH, Stonik JA, Brewer HB Jr: Human hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: evidence for the regulation of enzymic activity by a bicyclic phosphorylation cascade.Biochem Biophys Res Commun119 :488– 498,1984 .
   PubMedGoogle Scholar
• Beg ZH, Stonik JA, Brewer HB Jr: 3-Hydroxy-3-methylglutaryl coenzyme A reductase: regulation of enzymatic activity by phosphorylation and dephosphorylation.Proc Natl Acad Sci USA75 :3678– 3682,1978 .
   PubMed Web of Science ®Google Scholar
• Feingold KR, Wiley MH, Moser A, Siperstein MD: Altered activation state of hydroxymethyl glutaryl-coenzyme A reductase in liver tumors.Arch Biochem Biophys226 :231– 241,1983 .
   PubMedGoogle Scholar
• Gavey KL, Trujillo DL, Scallen TJ: Evidence for phosphorylation/dephosphorylation of rat liver acyl-CoA:cholesterol acyltransferase.Proc Natl Acad Sci USA80 :2171– 2174,1983 .
   PubMedGoogle Scholar
• Meigs TE, Simoni RD: Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase.Arch Biochem Biophys345 :1– 9,1997 .
   PubMed Web of Science ®Google Scholar
• Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia.Am J Cardiol81 :66B– 69B,1998 .
   PubMed Web of Science ®Google Scholar
• Vega GL, Grundy SM: Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.Am J Cardiol81 :36B– 42B,1998 .
   PubMedGoogle Scholar
• Bocan TM: Pleiotropic effects of HMG-CoA reductase inhibitors.Curr Opin Investig Drugs3 :1312– 1317,2002 .
   PubMedGoogle Scholar
• Chen H, Ikeda U, Shimpo M, Shimada K: Direct effects of statins on cells primarily involved in atherosclerosis.Hypertens Res23 :187– 192,2002 .
   Google Scholar
• Davignon J, Mabile L: [Mechanisms of action of statins and their pleiotropic effects].Ann Endocrinol (Paris)62 :101– 112,2001 .
   PubMed Web of Science ®Google Scholar
• Faggiotto A, Paoletti R: Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?Curr Atheroscler Rep2 :20– 25,2000 .
   PubMedGoogle Scholar
• Blumenthal RS: Statins: effective antiatherosclerotic therapy.Am Heart J139 :577– 583,2000 .
   PubMed Web of Science ®Google Scholar
• Bermudez EA, Ridker PM: C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease.Prev Cardiol5 :42– 46,2002 .
   PubMedGoogle Scholar
• Ridker PM: Connecting the role of C-reactive protein and statins in cardiovascular disease.Clin Cardiol26 :III39– 44,2003 .
   PubMedGoogle Scholar
• Bottorff M: ‘Fire and forget?’—pharmacological considerations in coronary care.Atherosclerosis 147 Suppl1 :S23– 30,1999 .
   Google Scholar
• Peters TK: Safety profile of fluvastatin.Br J Clin Pract Suppl77A :20– 23,1996 .
   PubMedGoogle Scholar
• Garnett WR: A review of current clinical findings with fluvastatin.Am J Cardiol78 :20– 25,1996 .
   PubMed Web of Science ®Google Scholar
• Carr-Lopez S, Exstrum T, Morse T, et al: Efficacy of three statins at lower maintenance doses.Clin Ther21 :331– 339,1999 .
   PubMedGoogle Scholar
• Heuer T, Gerards H, Pauw M, et al: [Toxic liver damage caused by HMG-CoA reductase inhibitor].Med Klin95 :642– 644,2000 .
   Google Scholar
• Chojnowska-Jezierska J: [Undesirable drug interactions of hypolipemic drugs].Pol Merkuriusz Lek9 :618– 620,2000 .
   PubMedGoogle Scholar
• von Keutz E, Schluter G: Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.Am J Cardiol82 :11J– 17J,1998 .
   PubMedGoogle Scholar
• Black DM, Bakker-Arkema RG, Nawrocki JW: An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.Arch Int Med158 :577– 584,1998 .
   PubMed Web of Science ®Google Scholar
• Buajordet I, Madsen S, Olsen H: [Statins—the pattern of adverse effects with emphasis on mental reactions. Data from a national and an international database].Tidsskr Nor Laegeforen117 :3210– 3213,1997 .
   PubMedGoogle Scholar
• Seelig MS, Rosanoff A:“The Magnesium Factor.” NY: Avery, Penguin-Putnam,2003 .
   Google Scholar
• Itoh K, Kawasaka T, Nakamura M: The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects.Br J Nutr78 :737– 750,1997 .
   PubMed Web of Science ®Google Scholar
• Rayssiguier Y: Role of magnesium and potassium in the pathogenesis of arteriosclerosis.Magnesium3 :226– 238,1984 .
   PubMedGoogle Scholar
• Rayssiguier Y: Magnesium, lipids and vascular diseases.Experimental evidence in animal models. Magnesium5 :182– 190,1986 .
   Google Scholar
• Mahfouz MM, Kummerow FA: Effect of magnesium deficiency on delta 6 desaturase activity and fatty acid composition of rat liver microsomes.Lipids24 :727– 32,1989 .
   PubMed Web of Science ®Google Scholar
• Mahfouz MM, Smith T, Kummerow FA: Changes of linoleic acid metabolism and cellular phospholipid fatty acid composition in LLC-PK cells cultured at low magnesium concentrations.Biochim Biophys Acta1006 :70– 74,1989 .
   PubMedGoogle Scholar
• Erasmus U:“Fats that Heal, Fats that Kill.” Burnaby BC Canada: Alive Books, pp277– 278,1993 .
   Google Scholar